ArticleJournal of inflammation research2025
Assessment of the Anti-Inflammatory Efficacy and Symptom Resolution Time of Kangfuxin Liquid Combined with Metronidazole in Recurrent Oral Ulcers.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Kangfuxin liquid enema plus adalimumab for ulcerative colitis: a retrospective cohort study.American journal of translational research · 2026Article
- Impact of zinc deficiency on the recurrence in aphthous stomatitis: A prospective case-control study.Bioinformation · 2026Article
- Article
- Effects of Kangfuxin on periodontal and masticatory outcome in periodontitis patients during implant supported rehabilitation.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluate the clinical efficacy and inflammatory modulation potential of Kangfuxin Liquid (KFXY; a traditional Chinese medicine recovery solution) in combination with metronidazole (MTZ) for the treatment of recurrent oral ulcers (ROU). Methods: A retrospective cohort study was conducted using clinical data from 117 ROU patients admitted between January 2021 and January 2023. Patients were categorized into two groups: a control group (n=58) treated with MTZ oral adhesive patches alone, and an observation group (n=59) receiving KFXY plus MTZ. Primary outcomes included clinical response rates, symptom resolution time (ulcer healing, pain relief, and eating ability), systemic inflammatory biomarkers (C-reactive protein [CRP], tumor necrosis factor-alpha [TNF-α], interleukin-6 [IL-6]), oral microbial flora composition (Veillonella, Streptococcus), and adverse event incidence. Results: Clinical Efficacy: The observation group demonstrated a significantly higher total response rate (94.92% vs 79.31%; P<0.05). Symptom Resolution: The KFXY-MTZ combination accelerated ulcer healing (P<0.05), reduced pain intensity (P<0.05), and improved oral intake (P<0.05) compared to MTZ alone. Inflammatory Modulation: Pre-treatment CRP, TNF-α, and IL-6 levels were comparable (P>0.05); post-treatment, these biomarkers were significantly lower in the observation group (P<0.05). Microbial Flora: Post-treatment levels of Veillonella and Streptococcus were significantly elevated in the observation group (P<0.05), indicating potential probiotic effects. Safety: Adverse event rates were similar between groups (control: 5.17%; observation: 6.78%; P>0.05). Conclusion: The KFXY-MTZ combination therapy exhibits robust anti-inflammatory and probiotic activities, accelerating ROU healing without compromising safety. These findings support its clinical utility as an integrative treatment strategy for ROU.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.